Affluent Medical SA (CVX) Stock Price & Analysis

1 Followers

CVX Stock Chart & Stats

€4.95-€0.33(-6.25%)

At close: Nov 05 5:30 PM GMT+1

Day’s Range: EUR 4.87 - EUR 5.34
52-Week Range: EUR 1.33 - EUR 7.56
Previous Close: EUR 5.28
Volume: N/A
Average Volume (3M): 19.20K
Market Cap: EUR 328.56M
Enterprise Value: EUR 204.58M
Total Cash (Recent Filing): EUR 7.02M
Total Debt (Recent Filing): EUR 19.48M
Price to Earnings (P/E): ―
Beta: 0.40
Next Earnings: N/A
EPS Estimate: N/A
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

Bulls Say, Bears Say

Bulls Say

Pipeline Breadth

A pipeline spanning structural heart and urology gives Affluent Medical multiple clinical and commercial opportunities rather than dependence on one indication. If development progresses, several candidates could support future revenue streams and diversify the company’s eventual product portfolio.

Minimally Invasive Focus

A focus on implantable, minimally invasive devices aligns the company with product categories intended to address significant clinical needs through less invasive procedures. This platform direction can support differentiated development opportunities as candidates advance through clinical and regulatory milestones.

Prior Revenue Scaling

Revenue expansion into 2024 shows that the business had previously demonstrated some ability to build commercial activity from a low base. Although the latest year reversed that progress, the earlier scaling provides evidence that development work can translate into operating revenue when products advance.

Bears Say

Zero Reported Revenue

Zero reported revenue highlights that Affluent Medical has not yet established a dependable commercial base. Without recurring sales, the company remains highly dependent on successful product development and future approvals before it can generate internally funded growth.

Persistent Losses

Negative gross profit and widening net losses indicate that current operations lack meaningful economic leverage. Continued losses can consume capital needed for clinical development, delay self-sufficiency, and make future profitability increasingly dependent on successful commercialization.

Funding And Leverage Risk

Persistent cash burn means the company is using funding to sustain operations rather than generating cash internally. Combined with higher debt and eroded equity, this reduces financial flexibility and increases dependence on external capital while the pipeline remains in development.

Affluent Medical SA News

Carvolix Reports October Share Capital and Voting Rights

Affluent Medical SA ( ($FR:CVX) ) just unveiled an update. Carvolix is a French medical technology company developing solutions for structural heart disease and stroke. Its portfolio includes artificial-intelligence- and

1d ago0JZ CVX

Carvolix Updates Share Capital and Voting Rights Structure

An announcement from Affluent Medical SA ( ($FR:CVX) ) is now available. French medtech group Carvolix, which develops AI-guided interventional mini-robots and biomimetic heart valves for structural heart disease and

4w ago0JZ CVX

Carvolix Strengthens Governance and Funding as TAVIPILOT and Kalios Advance Clinically

Affluent Medical SA ( ($FR:CVX) ) just unveiled an update. Carvolix has appointed technology investor and seasoned board member Anne Lange as chair, reinforcing its governance with new observers and

1M ago0JZ CVX

Carvolix files FDA submission for TAVIPILOT robot amid expanding U.S. TAVI market

Affluent Medical SA ( ($FR:CVX) ) just unveiled an announcement. Carvolix has filed a 510(k) application with the U.S. Food and Drug Administration for its TAVIPILOT robot, the hardware component

1M ago0JZ CVX

Carvolix updates share capital and voting rights structure

The latest announcement is out from Affluent Medical SA ( ($FR:CVX) ). Carvolix has disclosed updated figures for its share capital and voting rights as of 31 August 2026, reporting

1M ago0JZ CVX

Carvolix Files for CE Marking to Launch TAVIPILOT AI TAVI Software in Europe

The latest update is out from Affluent Medical SA ( ($FR:CVX) ). Carvolix has submitted the regulatory dossier for its TAVIPILOT AI software to obtain EU CE marking, aiming to

1M ago0JZ CVX

Carvolix and Truffle Capital Launch Franco-Saudi SAF-MD Program and Plan Saudi MedTech Hub

Affluent Medical SA ( ($FR:CVX) ) has issued an announcement. Truffle Capital and its portfolio company Carvolix SA, together with Carvolix Saudi LLC, have launched the SAF-MD Saudi–French Medical Exchange

2M ago0JZ CVX

Carvolix Secures €30 Million Structured Debt to Fund AI-Driven Cardio Robotics Push

Affluent Medical SA ( ($FR:CVX) ) has shared an announcement. Carvolix has secured up to €30 million in structured debt financing from Claret Capital Partners, comprising senior secured convertible and

3M ago0JZ CVX

Carvolix Updates Market on Share Capital and Voting Rights Structure

Affluent Medical SA ( ($FR:CVX) ) has provided an update. Carvolix has reported that its share capital as of 31 July 2026 comprises 62,275,177 shares, corresponding to a theoretical total

3M ago0JZ CVX

ODDO BHF Launches Outperformance Coverage on Carvolix, Signaling Strong Upside Potential

Affluent Medical SA ( ($FR:CVX) ) has shared an announcement. Carvolix has gained fresh attention in the equity markets after ODDO BHF initiated coverage of the stock with an Outperformance

3M ago0JZ CVX

CVX FAQ

What was Affluent Medical SA’s price range in the past 12 months?

Affluent Medical SA lowest stock price was €1.33 and its highest was €7.56 in the past 12 months.

What is Affluent Medical SA’s market cap?

Affluent Medical SA’s market cap is €328.56M.

When is Affluent Medical SA’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Affluent Medical SA’s earnings last quarter?

Affluent Medical SA released its earnings results on Sep 30, 2026. The company reported -€0.25 earnings per share for the quarter.

Is Affluent Medical SA overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does Affluent Medical SA pay dividends?

Affluent Medical SA does not currently pay dividends.

What is Affluent Medical SA’s EPS estimate?

Affluent Medical SA’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Affluent Medical SA have?

Affluent Medical SA has 62,278,385 shares outstanding.

What happened to Affluent Medical SA’s price movement after its last earnings report?

Affluent Medical SA reported an EPS of -€0.25 in its last earnings report. Following the earnings report the stock price went up 4.332%.

Which hedge fund is a major shareholder of Affluent Medical SA?

Currently, no hedge funds are holding shares in FR:CVX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description